Pulnovo Medical Reports PADN Trial Results in NEJM
Shanghai, China, September 3, 2026 Pulnovo Medical announced clinical results from the PADN-HF-PH randomized controlled trial, evaluating pulmonary artery...
NEJM
Advertisement
Revolution Medicines Reports NEJM Data for RASONQUE in NSCLC
REDWOOD CITY, Calif., Sept. 2, 2026 Revolution Medicines, Inc. (Nasdaq: RVMD), a commercial-stage oncology company focused on RAS-driven cancers,...
Latigo Biotherapeutics Reports NEJM-Published Positive LTG-001 Acute Pain Trial Results
THOUSAND OAKS, Calif., July 29, 2026 Latigo Biotherapeutics announced that The New England Journal of Medicine (NEJM) has published...
Sana Reports Long-Term Type 1 Diabetes Data
SEATTLE, July 13, 2026 Sana Biotechnology announced the publication of long-term clinical findings in The New England Journal of...
Rhythm Publishes Phase 3 IMCIVREE Data in NEJM
BOSTON, Mass., July 8, 2026 Rhythm Pharmaceuticals announced that the New England Journal of Medicine (NEJM) has published the...
Advertisements
BridgeBio Reports Positive Phase 3 Oral Infigratinib Results for Achondroplasia
PALO ALTO, Calif., June 28, 2026 BridgeBio Pharma announced that positive results from its pivotal Phase 3 PROPEL 3...
BeOne Medicines Reports Positive Phase 3 HERIZON-GEA Results at ASCO 2026
CHICAGO, Illinois and SAN CARLOS, California — May 27, 2026 BeOne Medicines announced new clinical findings from the Phase...
Moderna Publishes Positive Phase 3 Clinical Data for mRNA-1010 Seasonal Influenza Vaccine in New England Journal of Medicine
CAMBRIDGE, Mass., May 6, 2026 Moderna announced the publication of pivotal Phase 3 clinical safety and efficacy data for...
Revolution Medicines Publishes Daraxonrasib Pancreatic Cancer Data in NEJM
Redwood City, Calif., May 6, 2026 Revolution Medicines, Inc. announced the publication of important Phase 1/2 clinical trial data...
Novo Nordisk Reports Strong Phase 3 Results for Denecimig in Hemophilia A
PLAINSBORO, N.J. & BAGSVAERD, Denmark, April 29, 2026 Novo Nordisk has announced that its investigational therapy denecimig (Mim8) significantly...
Advertisement
